August 2012
-
According to ARS Pharmaceuticals, the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the company’s marketing application for EURneffy adrenaline nasal spray for the emergency treatment of anaphylaxis in patients who weigh more than 30… Read more . . .
-
BiomX announced that it has initiated a Phase 2b study of its BX004 inhaled phage cocktail cystic fibrosis patients with chronic P. aeruginosa lung infections. BiomX had said in November 2023 that it planned to advance… Read more . . .
-
Oragenics, which recently announced that it had raised approximately $16.5 million for Phase 2 development of its OPN-002 neurosteroid nasal powder for the treatment of mild traumatic brain injury, says that Sterling Pharma Services will… Read more . . .
-
Aptar Pharma announced that it has acquired OINDP specialist CDMO Mod3 Pharma (formerly Enteris Biopharma). According to Mod3’s web site, Enteris was created in 2013 with assets and personnel from Unigene, which manufactured Fortical calcitonin… Read more . . .
-
Hong Kong-based Guangdong Hengrui Pharmaceuticals’s parent company Jiangsu Hengrui Pharmaceuticals announced that Guangdong Hengrui has received approval from the Chinese National Medical Products Administration (NMPA) for a clinical trial of its HRS-9821 DPI, which the… Read more . . .
-
Merck has announced that it will acquire Ohtuvarye inhaled ensifentrine maker Verona Pharma for a total of approximately $10 billion. Ohtuvarye, which is delivered via jet nebulizer, was approved by the FDA in June 2024… Read more . . .
-
Evoke Pharma announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a continuation of US Patent No. 11,517,545 (“Treatment of Moderate and Severe Gastroparesis”), which was issued… Read more . . .
-
Oragenics announced that it has raised approximately $16.5 million in a Series H funding round, with proceeds going toward repayment of a $3 million bridge loan and continued development of the company’s OPN-002 neurosteroid nasal… Read more . . .
-
German startup Ebenbuild has received a €2.3 million grant plus a commitment for up to an additional €10 million in future investments from the European Innovation Council (EIC) Accelerator program, the company said. The funding… Read more . . .
-
Beckley Psytech and atai Life Sciences have announced that a Phase 2b trial of Beckley’s BPL-003 intranasal mebufotenin (5-MeO-DMT) in patients with treatment-resistant depression met its primary endpoint, demonstrating a significant reduction in symptoms of depression… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.